Table 3.
Summary of the peri-operative success rate of the target lesions with hypofluorecence compared with the parenchyma, based on the pathological results
| Author | Journal (published year) | % of malignant in total cases | Total | Clear cell carcinoma | Malignant pathological results |
Benign pathological results |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chromophobe | Papillary | Cystic clear cell | Others | Oncocytoma | Angiomyolipoma | Cyst | Others | |||||
| Tobis et al. | Urology | 82.3% | 94.1% | 100% | 100% | 100% | 100% | 100% | 0% | |||
| [16] | (2012) | (14/17) | (16/17) | (8/8) | (1/1) | (4/4) | (1/1) | (2/2) | (0/1) | |||
| Tobis et al. | J Endurol | 68.5% | 68.4% | 100% | 100% | 0% | 0% | 0% | ||||
| [15] | (2012) | (13/19) | (13/19) | (10/10) | (3/3) | (0/1) | (0/2) | (0/3) | ||||
| Angell et al. | J Urol | 78.9% | 85.5% | 83.3 | 54.4% | 66.6% | 100% | |||||
| [8] | (2013) | (60/76) | (65/76) | (55/60) | (6/11) | (2/3) | (2/2) | |||||
| Manny et al. | J Endurol | 77.0% | 75% | 95.8% | 100% | 100% | 0% | 0% | 100% | 0% | 0% | 0% |
| [13] | (2013) | (77/100) | (75/100) | (46/48) | (6/6) | (13/13) | (0/7) | (0/3) | (8/8) | (0/8) | (0/5) | (0/2) |
| Our study | 2018 | 90.5% | 76.1% | 70.5% | 100% | 100% | 100% | |||||
| (19/21) | (16/21) | (12/17) | (1/1)) | (1/1) | (2/2) | |||||||